This article was originally published in The Gray Sheet
Blood coagulation and hemostasis monitoring firm expects to introduce the InRatio coagulation monitoring system to the U.S. market in mid-2000. The firm holds several patents for its PT testing technology and plans to file for regulatory clearance in the U.S. and Europe later this year. The device will provide PT measurements at home or in the doctor's office from a fingerstick sample. The worldwide coagulations testing market is expected to exceed $500 mil. by 2004
You may also be interested in...
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.
As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.
Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.